0001485003-21-000110.txt : 20210510
0001485003-21-000110.hdr.sgml : 20210510
20210510204534
ACCESSION NUMBER: 0001485003-21-000110
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210503
FILED AS OF DATE: 20210510
DATE AS OF CHANGE: 20210510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Henderson Jane
CENTRAL INDEX KEY: 0001422304
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36296
FILM NUMBER: 21909252
MAIL ADDRESS:
STREET 1: C/O ELEVEN BIOTHERAPEUTICS, INC.
STREET 2: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sesen Bio, Inc.
CENTRAL INDEX KEY: 0001485003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262025616
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8550
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc.
DATE OF NAME CHANGE: 20100223
4
1
wf-form4_162069392081695.xml
FORM 4
X0306
4
2021-05-03
0
0001485003
Sesen Bio, Inc.
SESN
0001422304
Henderson Jane
C/O SESEN BIO, INC.
245 FIRST STREET, SUITE 1800
CAMBRIDGE
MA
02142
1
0
0
0
Stock Option
2.79
2021-05-03
4
A
0
92500
0
A
2031-05-03
Common Stock
92500.0
92500
D
The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis.
/s/ Monica Forbes, as attorney-in-fact
2021-05-10